Recent advances in drug discovery research have led to the development of numerous drug candidate compounds with high ...
Median overall survival (OS) and progression-free survival (PFS) in uterine carcinosarcoma (UCS) both improved with paclitaxel and carboplatin as compared with a standard-of-care regimen, a randomized ...
Explore how paclitaxel and innovative drug delivery systems are changing cancer treatment and improving therapeutic outcomes.
Long-term data from the Veterans Health Administration (VHA) are in line with the conclusions of several recent trials and registries that dispute the existence of an increased mortality signal with ...
Dr. Nicoletta Colombo breaks down KEYNOTE B96 showing Keytruda plus paclitaxel, with or without bevacizumab, improves ...
The United States Food and Drug Administration today, in a letter to healthcare providers, reversed its restrictions on the use of paclitaxel-based therapies in peripheral vascular interventions (PVIs ...
Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression The enrollment goal of 125 patients was met. Median age was 46 years (range, 21-65 years), ...
Pembrolizumab plus weekly paclitaxel, with investigator-choice bevacizumab, achieved statistically significant PFS and OS ...
In the article that accompanies this editorial, Powell et al 5 present the results of a randomized phase III trial comparing carboplatin/paclitaxel with ifosfamide ...
Please provide your email address to receive an email when new articles are posted on . Survival outcomes did not differ for patients with HNSCC who received radiotherapy with carboplatin-paclitaxel ...
A recent large German study has shown that a new combination therapy for breast cancer treatment leads to a lowered risk of the disease coming back. A commentary on this landmark clinical trial has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results